DR. MOORE BRINGS DEEP R&D EXPERIENCE TO THE
COMPANY AS IT ADVANCES ITS VISION TO BRING NOVEL EPIGENETIC EDITING
THERAPEUTICS TO PATIENTS
BOSTON, July 18,
2024 /PRNewswire/ -- Chroma Medicine, Inc., (Chroma)
a genomic medicine company pioneering single-course epigenetic
editing therapeutics, today announced the appointment of
Melissa J. Moore, Ph.D., to its
Board of Directors.
"Melissa brings decades of experience directing RNA research and
drug development at leading pharma companies and in academia," said
Catherine Stehman-Breen, M.D., CEO
of Chroma. "Her deep knowledge will benefit us as we advance our
platform of highly potent and durable epigenetic editors to
patients, enabling a new class of genomic medicines."
Currently serving as a Board Director and Scientific Advisory
Board member for multiple biotechnology companies, Dr. Moore
previously held the role of Chief Scientific Officer, Platform
Research, at Moderna, where she led the early-stage research teams
developing the company's platform technologies in mRNA design and
delivery, including the COVID-19 vaccine. She co-founded the RNA
Therapeutics Institute at the University of
Massachusetts Medical School, where she was a Professor of
Biochemistry & Molecular Pharmacology, Eleanor Eustis
Farrington Chair in Cancer Research, and a long-time Investigator
at the Howard Hughes Medical Institute.
Dr. Moore is an elected member of the National Academy of
Sciences, a Fellow of the American Academy of Arts and Sciences,
and recipient of the RNA Society Lifetime Achievement Award. She
holds a B.S. in Chemistry and Biology from the College of William and Mary, and a Ph.D. in
Biological Chemistry from MIT.
"Epigenetic editing is a rapidly growing field poised to
transform the gene editing landscape," said Dr. Moore. "Chroma's
robust platform has demonstrated specific and durable regulation of
gene expression without cutting or nicking the DNA, offering great
potential to fuel novel, single-course medicines for serious
genetic diseases. I am excited to join in its mission to bring
these therapeutics to patients."
About Chroma Medicine
Chroma Medicine is a
biotechnology company pioneering a new class of genomic medicines
that harness epigenetics, nature's innate mechanism for gene
regulation, to deliver precise, programmable single-course
therapeutics while preserving genomic integrity. The company's
modular platform enables development of medicines that can address
a wide range of complex diseases, whether they require silencing,
activation, or targeting multiple genes at once. Chroma was founded
by the world's foremost experts in genomic research and is led by a
veteran team of industry leaders and scientists with deep
experience in genomic medicine, drug discovery, and development.
For more information, please visit chromamedicine.com or
follow us on LinkedIn and X (formerly known as
Twitter).
View original content to download
multimedia:https://www.prnewswire.com/news-releases/chroma-medicine-appoints-renowned-rna-scientist-melissa-moore-to-board-of-directors-302200845.html
SOURCE Chroma Medicine